Helicobacter pylori: Routes of Infection, Antimicrobial Resistance, and Alternative Therapies as a Means to Develop Infection Control DOI Creative Commons
Ayman Elbehiry, Adil Abalkhail, Nuha Anajirih

et al.

Diseases, Journal Year: 2024, Volume and Issue: 12(12), P. 311 - 311

Published: Dec. 3, 2024

Helicobacter pylori (H. pylori) is a Gram-negative, spiral-shaped bacterium that colonizes the gastric epithelium and associated with range of gastrointestinal disorders, exhibiting global prevalence approximately 50%. Despite availability treatment options, H. frequently reemerges demonstrates increasing antibiotic resistance, which diminishes efficacy conventional therapies. Consequently, it imperative to explore non-antibiotic alternatives mitigate inappropriate use antibiotics. This review examines infection, encompassing transmission pathways, modalities, eradication strategies. Additionally, discusses alternative therapeutic approaches such as probiotics, anti-biofilm agents, phytotherapy, phototherapy, phage therapy, lactoferrin vaccine development. These strategies aim reduce antimicrobial resistance enhance outcomes for infections. While therapies can maintain low bacterial levels, they do not achieve complete pylori. are designed bolster immune response, minimize side effects, provide gastroprotective benefits, rendering them suitable adjunctive alongside treatments. Probiotics may serve therapy pylori; however, their effectiveness monotherapy limited. Photodynamic exhibit potential in targeting infections, including those caused by drug-resistant strains, without The development reliable also critical identifies candidate antigens VacA, CagA, HspA, along various formulations, vector-based subunit vaccines. Some vaccines have demonstrated clinical trials, while others shown robust protection preclinical studies. Nevertheless, each aforementioned requires thorough evaluation ascertain efficacy, cost-effectiveness, patient compliance.

Language: Английский

Trends of antibiotic resistance of Helicobacter pylori in Moscow DOI Creative Commons
И. В. Маев, Д. Н. Андреев, Aleksei К. Fomenko

et al.

Terapevticheskii arkhiv, Journal Year: 2025, Volume and Issue: 97(2), P. 163 - 168

Published: March 26, 2025

To determine the trends of primary antibiotic resistance Helicobacter pylori strains isolated from patients living in Moscow. As part a clinical and laboratory study, 123 gastric biopsy specimens H. pylori-infected were analyzed 2015 to 2024. infection was verified by rapid urease test 13C-urease breath test. The anaerobic culture technique used. After identifying pure culture, its susceptibility four antibacterial agents (amoxicillin - AMC, clarithromycin CLR, metronidazole MET, tetracycline TET) determined disc diffusion method. According data, overall pool (n=123) samples AMC 4.88%, CLR 16.26%, TET 3.25%, MET 46.34%. Dual detected 4.06% strains. Among collected 2019 (n=28), 0.0%, 10.71%, 50.0%. structure 2020 2024 (n=95) as follows: 6.32%, 17.89%, 4.21%, 45.26%. There is gradual tendency increase such Moscow, which consistent with data other studies. This negative trend may eventually lead decreased effectiveness currently used eradication therapy regimens Russia.

Language: Английский

Citations

0
Helicobacter pylori: Routes of Infection, Antimicrobial Resistance, and Alternative Therapies as a Means to Develop Infection Control DOI Creative Commons
Ayman Elbehiry, Adil Abalkhail, Nuha Anajirih

et al.

Diseases, Journal Year: 2024, Volume and Issue: 12(12), P. 311 - 311

Published: Dec. 3, 2024

Helicobacter pylori (H. pylori) is a Gram-negative, spiral-shaped bacterium that colonizes the gastric epithelium and associated with range of gastrointestinal disorders, exhibiting global prevalence approximately 50%. Despite availability treatment options, H. frequently reemerges demonstrates increasing antibiotic resistance, which diminishes efficacy conventional therapies. Consequently, it imperative to explore non-antibiotic alternatives mitigate inappropriate use antibiotics. This review examines infection, encompassing transmission pathways, modalities, eradication strategies. Additionally, discusses alternative therapeutic approaches such as probiotics, anti-biofilm agents, phytotherapy, phototherapy, phage therapy, lactoferrin vaccine development. These strategies aim reduce antimicrobial resistance enhance outcomes for infections. While therapies can maintain low bacterial levels, they do not achieve complete pylori. are designed bolster immune response, minimize side effects, provide gastroprotective benefits, rendering them suitable adjunctive alongside treatments. Probiotics may serve therapy pylori; however, their effectiveness monotherapy limited. Photodynamic exhibit potential in targeting infections, including those caused by drug-resistant strains, without The development reliable also critical identifies candidate antigens VacA, CagA, HspA, along various formulations, vector-based subunit vaccines. Some vaccines have demonstrated clinical trials, while others shown robust protection preclinical studies. Nevertheless, each aforementioned requires thorough evaluation ascertain efficacy, cost-effectiveness, patient compliance.

Language: Английский

Citations

0